title: [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
abstract: A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects between the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.
authors.affiliation: The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Hideki
authors.initials: H
authors.lastname: Sakai
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Igawa
authors.forename: Toru
authors.initials: T
authors.lastname: Onita
authors.forename: Masataka
authors.initials: M
authors.lastname: Furukawa
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Hakariya
authors.forename: Mikio
authors.initials: M
authors.lastname: Hayashi
authors.forename: Fukuzo
authors.initials: F
authors.lastname: Matsuya
authors.forename: Yohei
authors.initials: Y
authors.lastname: Shida
authors.forename: Naoki
authors.initials: N
authors.lastname: Nishimura
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yogi
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Tsurusaki
authors.forename: Kousuke
authors.initials: K
authors.lastname: Takehara
authors.forename: Koichiro
authors.initials: K
authors.lastname: Nomata
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Shiraishi
authors.forename: Takefumi
authors.initials: T
authors.lastname: Shono
authors.forename: Daiyu
authors.initials: D
authors.lastname: Aoki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanetake
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage* / Q000009:adverse effects; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil